Breadcrumb
Presentation Materials
A Phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 with solid tumors
Material Type: Presentation
A first-in-human trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in advanced solid tumors expressing B7-H6
Material Type: Poster
A Phase I trial of BI 1810631, a HER2 inhibitor, as monotherapy in advanced or metastatic solid tumors with HER2 aberrations
A Phase Ia/Ib study of BI 907828 in combination with immune checkpoint inhibitor(s) in patients with advanced solid tumors
